Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2'-Deoxy-2'-fluoroguanosine is a synthetic nucleoside analog characterized by the substitution of a fluorine atom at the 2' position of the deoxyribose sugar ring of guanosine. It functions as a potent antiviral agent, demonstrating significant activity against a range of viruses, most notably influenza (A and B) and herpes simplex viruses (HSV-1 and HSV-2). The mechanism of action involves the intracellular phosphorylation of the compound to its active triphosphate form, which then competes with natural guanosine triphosphate (GTP) for incorporation into viral nucleic acids. This process leads to the inhibition of viral RNA-directed RNA polymerase (RdRp) in influenza viruses, effectively blocking viral transcription and replication. In herpesviruses, it similarly targets viral DNA polymerase. While it has been extensively studied in preclinical research for its antiviral properties, it is primarily utilized as a research tool and has not been developed into a commercial pharmaceutical product by a specific company.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2'-deoxy-2'-fluoroguanosine.